Cargando…

Docetaxel (Taxotere): a new anti-cancer drug with promising potential?

Detalles Bibliográficos
Autor principal:	Verweij, J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033506/ https://www.ncbi.nlm.nih.gov/pubmed/7914419

Ejemplares similares

Interaction of Docetaxel (“Taxotere”) with Human P‐Glycoprotein
por: Shirakawa, Katsuro, et al.
Publicado: (1999)

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
por: de Wit, R., et al.
Publicado: (1998)

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
por: Sulkes, A., et al.
Publicado: (1994)

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells.
por: Hennequin, C., et al.
Publicado: (1995)

Antitumor Effects of Combining Docetaxel (Taxotere) with the Antivascular Action of Ultrasound Stimulated Microbubbles
por: Goertz, David E., et al.
Publicado: (2012)

The Effect of Docetaxel (Taxotere(®)) on Human Gastric Cancer Cells Exhibiting Low-Dose Radiation Hypersensitivity
por: Balcer-Kubiczek, Elizabeth K., et al.
Publicado: (2008)

Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial
por: Spielmann, M, et al.
Publicado: (2002)

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
por: Sternberg, C. N., et al.
Publicado: (1994)

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
por: Cerny, T., et al.
Publicado: (1994)

Physical and chemical stability of Taxotere(®) (docetaxel) one-vial (20 mg/ml) infusion solution following refrigerated storage
por: Hart, M, et al.
Publicado: (2010)

Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II
por: Kim, Sung-Bae, et al.
Publicado: (2015)

Safety and efficacy of single‐agent docetaxel (Taxotere) administered weekly in non‐small cell lung carcinoma patients in Korea: An observational study
por: Lim, Sun Min, et al.
Publicado: (2015)

Multicellular Tumor Spheroids for Evaluation of Cytotoxicity and Tumor Growth Inhibitory Effects of Nanomedicines In Vitro: A Comparison of Docetaxel-Loaded Block Copolymer Micelles and Taxotere®
por: Mikhail, Andrew S., et al.
Publicado: (2013)

Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
por: Tesei, Anna, et al.
Publicado: (2011)

Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells
por: Li, Yiwei, et al.
Publicado: (2005)

Docetaxel: promising and novel combinations in ovarian cancer
por: Mäenpää, J U
Publicado: (2003)

A magnetic antibody-conjugated nano-system for selective delivery of Ca(OH)(2) and taxotere in ovarian cancer cells
por: Taheri-Ledari, Reza, et al.
Publicado: (2022)

Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review
por: Raufi, Ali, et al.
Publicado: (2015)

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
por: Jensen, P. B., et al.
Publicado: (1997)

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review
por: Engels, F K, et al.
Publicado: (2005)

Chitosomes Loaded with Docetaxel as a Promising Drug Delivery System to Laryngeal Cancer Cells: An In Vitro Cytotoxic Study
por: Moya-Garcia, Christian R., et al.
Publicado: (2023)

Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2
por: Boudny, V, et al.
Publicado: (2002)

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response
por: Boniface, Christopher T., et al.
Publicado: (2022)

ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol
por: Ntekim, Atara I., et al.
Publicado: (2020)

Corrigendum: Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response
por: Boniface, Christopher T., et al.
Publicado: (2023)

New Nitric Oxide-Releasing Compounds as Promising Anti-Bladder Cancer Drugs
por: Varela, María, et al.
Publicado: (2023)

Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
por: Gomez Marti, Juan Luis, et al.
Publicado: (2023)

Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis
por: Choi, Hong Y., et al.
Publicado: (2021)

Cannabidiol (CBD) as a Promising Anti-Cancer Drug
por: Seltzer, Emily S., et al.
Publicado: (2020)

Candidate Markers That Associate with Chemotherapy Resistance in Breast Cancer through the Study on Taxotere-Induced Damage to Tumor Microenvironment and Gene Expression Profiling of Carcinoma-Associated Fibroblasts (CAFs)
por: Rong, Guohua, et al.
Publicado: (2013)

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
por: Li, Jing, et al.
Publicado: (2013)

New and promising anti-bacterials: Can this promise be sustained?
por: Saran, Sai, et al.
Publicado: (2020)

Docetaxel Loaded in Copaiba Oil-Nanostructured Lipid Carriers as a Promising DDS for Breast Cancer Treatment
por: de Carvalho, Fabiola Vieira, et al.
Publicado: (2022)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

Drug–Drug interactions of docetaxel in patients with breast cancer based on insurance claims data
por: Shin, Kwang-Hee, et al.
Publicado: (2023)

KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine
por: Casper, Corey, et al.
Publicado: (2022)

Assessment of herbal drugs for promising anti-Candida activity
por: Soliman, Sameh S. M., et al.
Publicado: (2017)

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
por: Arichi, Naoko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kscpotkg88be00vll4d2b4hg0j